DG Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

DG Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-499,271	Closed	-$2.25M	–	43
2022 Q3	$2.25M	Sell	499,271 -123,297	-20%	-$562K	0.99%	17
2022 Q2	$2.49M	Buy	622,568 +100,000	+19%	+$474K	0.89%	19
2022 Q1	$3.83M	Sell	522,568 -97,139	-16%	-$581K	0.77%	30
2021 Q4	$3.48M	Buy	619,707 +75,485	+14%	+$479K	0.57%	31
2021 Q3	$3.48M	Buy	+544,222	New	+$3.5M	0.71%	34
2021 Q1	–	Sell	-443,331	Closed	-$7.51M	–	132
2020 Q4	$7.51M	Buy	443,331 +26,239	+6%	+$393K	3.18%	14
2020 Q3	$5.35M	Buy	417,092 +129,920	+45%	+$1.64M	3.22%	14
2020 Q2	$4.05M	Buy	+287,172	New	+$3.63M	3.32%	14

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

DG Capital Management's PRVB Position: Q4 2022 in Review

DG Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2022, closing a stake of 499,271 shares — an estimated $2.25M sold.

DG Capital Management first reported a position in PRVB in Q2 2020 and held it in 8 quarters. The position peaked at $7.51M in Q4 2020. 133 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

DG Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
DG Capital Management sold 499,271 Provention Bio, Inc. Common Stock shares in Q4 2022, an estimated $2.25M.
DG Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
DG Capital Management's Provention Bio, Inc. Common Stock position peaked at $7.51M in Q4 2020.
133 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2022.

Based on DG Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.